Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Ziopharm Oncology, Inc., which rebranded to Alaunos Therapeutics, Inc. (NASDAQ: TCRT) in January 2022, was a clinical-stage biopharmaceutical company. It focused on developing T-cell receptor (TCR) therapies for cancer, aiming to harness the power of the immune system to target and destroy solid tumors. The company utilized a non-viral T-cell engineering platform called Sleeping Beauty. Following strategic challenges and restructuring efforts, Alaunos Therapeutics filed for Chapter 7 bankruptcy in October 2023 and ceased operations.
Served as the primary corporate office, overseeing administrative, research coordination, and strategic operations before cessation of activities.
Likely standard office space within a commercial office park, equipped for administrative and executive functions. Specific architectural details are not widely publicized.
Prior to its difficulties, the culture likely emphasized scientific innovation, collaboration, and a fast-paced environment typical of clinical-stage biotech companies focused on oncology.
The Houston headquarters marked a shift from its previous Boston base (as Ziopharm) and was intended to be the hub for its renewed focus under the Alaunos brand. It was central to its operational and strategic leadership before the company's dissolution.
The company's operations were primarily based in the United States, focusing on research, development, and clinical trials. While clinical trials may have involved international sites, it did not maintain significant independent global office infrastructure. Its primary focus markets and operational activities were within the U.S.
11000 Equity Drive, Suite 150
Houston
TX
USA
Address: One First Avenue, Parris Building #34, Navy Yard Plaza, Boston, MA 02129 (Former Ziopharm HQ)
Focused on research and development, corporate strategy, and leveraging the dense network of academic institutions, hospitals, and biotech companies in the Greater Boston area.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ziopharm Oncology' leadership includes:
Ziopharm Oncology has been backed by several prominent investors over the years, including:
The 12 months leading to and including the bankruptcy in October 2023 saw significant executive turnover as the company navigated severe financial distress, restructuring efforts, and ultimately ceased operations. Most executives departed as part of this process.
Discover the tools Ziopharm Oncology uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Companies like Alaunos Therapeutics typically use common email formats. While no longer operational, a common format observed for biotech companies is [first_initial][last]@[companydomain].com.
[first_initial][last]@alaunos.com
Format
jdoe@alaunos.com
Example
0%
Success rate
Fierce Biotech • October 25, 2023
Alaunos Therapeutics has filed for Chapter 7 bankruptcy and will cease operations. The decision follows a strategic review initiated earlier in the year, during which the company explored various alternatives, including partnerships or a sale....more
PR Newswire (Company Press Release) • June 6, 2023
Alaunos Therapeutics announced the appointment of Robert Postma as its new President and Chief Executive Officer, effective immediately. Mr. Postma succeeded Kevin S. Boyle, Sr., who departed the company....more
GlobeNewswire (Company Press Release) • January 26, 2022
Ziopharm Oncology, Inc. announced it has changed its name to Alaunos Therapeutics, Inc. The change reflects the company's evolution and its focus on developing T-cell receptor (TCR) therapies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ziopharm Oncology, are just a search away.